Sosei is taking over Activus Pharma of Chiba, Japan in a stock-exchange transaction. Activus' nanoparticle drug formulation technologies will form the basis of Sosei's new platform technology.
Sosei expects the technology to generate new drug candidates for internal development as well as partnerships that will allow the firm to realize revenue from this technology.
Activus says that its Pure Nanoparticle Technology (APNT) unlike other nanoparticle-processing technologies keeps compounds virtually free from contamination. APNT utilizes salt and polyol for grinding of APIs. The polyol serves as a binder that connects the compound and the salt. The compound is broken into pieces by the grinding force of the salt particles.
The salt particles are broken into pieces and small salt particles can be removed finally by washing with water. Also, polyol can be removed by washing with water. Therefore, contaminations that present a danger to human body do not occur.
At the same time it can yield pharmaceutical ingredients with particle sizes ranging from 50 to 300 nm levels. Thus, APNT enables the development of injections, ophthalmic solutions, and inhalations with poorly soluble compounds where high-purity is required.